Chronic heart failure management in primary healthcare in Poland : results of a nationwide cross-sectional study by Wizner, Barbara et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=igen20
European Journal of General Practice
ISSN: 1381-4788 (Print) 1751-1402 (Online) Journal homepage: https://www.tandfonline.com/loi/igen20
Chronic heart failure management in primary
healthcare in Poland: Results of a nationwide
cross-sectional study
Barbara Wizner, Małgorzata Fedyk-Łukasik, Grzegorz Opolski, Tomasz
Zdrojewski, Adam Windak, Marcin Czech, Jacek S. Dubiel, Michał Marchel,
Krzysztof Rewiuk, Tomasz Rywik, Jerzy Korewicki & Tomasz Grodzicki
To cite this article: Barbara Wizner, Małgorzata Fedyk-Łukasik, Grzegorz Opolski, Tomasz
Zdrojewski, Adam Windak, Marcin Czech, Jacek S. Dubiel, Michał Marchel, Krzysztof Rewiuk,
Tomasz Rywik, Jerzy Korewicki & Tomasz Grodzicki (2018) Chronic heart failure management in
primary healthcare in Poland: Results of a nationwide cross-sectional study, European Journal of
General Practice, 24:1, 1-8, DOI: 10.1080/13814788.2017.1368490
To link to this article:  https://doi.org/10.1080/13814788.2017.1368490
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 22 Nov 2017. Submit your article to this journal 
Article views: 1065 View related articles 
View Crossmark data
RESEARCH ARTICLE
Chronic heart failure management in primary healthcare in Poland: Results
of a nationwide cross-sectional study
Barbara Wiznera , Małgorzata Fedyk-Łukasika, Grzegorz Opolskib , Tomasz Zdrojewskic, Adam Windakd,
Marcin Czeche,f, Jacek S. Dubielg, Michał Marchelb, Krzysztof Rewiuka, Tomasz Rywikh, Jerzy Korewickih and
Tomasz Grodzickia
aDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland; bDepartment of
Cardiology, Medical University of Warsaw, Warsaw, Poland; cDepartment of Preventive Medicine and Education, Medical University of
Gdansk, Gdansk, Poland; dDepartment of Family Medicine, Jagiellonian University Medical College, Krakow, Poland; eDepartment of
Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland; fBusiness School, Warsaw University of Technology, Warsaw,
Poland; gDepartment of Cardiology, Jagiellonian University Medical College and University Hospital, Krakow, Poland; hDepartment of
Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland
KEY MESSAGES
 More attention is needed to include echocardiography in diagnostics of CHF in older patients, also due to a
higher prevalence of chronic comorbidities associated with preserved ejection fraction.
 Most CHF patients received drug classes in accordance with guidelines, and no age/gender-related gap was
observed in the neurohormonal blockade.
ABSTRACT
Background: Organizational and educational activities in primary care in Poland have been
introduced to improve the chronic heart failure (CHF) management.
Objectives: To assess the use of diagnostic procedures, pharmacotherapy and referrals of CHF in
primary care in Poland.
Methods: The cross-sectional survey was conducted in 2013, involving 390 primary care centres
randomly selected from a national database. Trained nurses contacted primary care physicians
who retrospectively filled out the study questionnaires on the previous year’s CHF management
in the last five patients who had recently visited their office. The data on diagnostic and treat-
ment procedures were collected.
Results: The mean age±SD of the 2006 patients was 72±11 years, 45% were female, and 56%
had left ventricular ejection fraction <50%. The percentage of the CHF patients diagnosed
based on echocardiography was 67% and significantly increased during the last decade.
Echocardiography was still less frequently performed in older patients (80 years) than in the
younger ones (respectively 50% versus 72%, P<0.001) and in women than in men (62% versus
71%, P<0.001). The percentage of the patients treated with b-blocker alone was 88%, but those
with a combination of angiotensin inhibition 71%. The decade before, these percentages
were 68% and 57%, respectively. Moreover, an age-related gap observed in the use of the
above-mentioned therapy has disappeared.
Conclusion: The use of echocardiography in CHF diagnostics has significantly improved in pri-
mary care in Poland but a noticeable inequality in the geriatric patients and women remains.
Most CHF patients received drug classes in accordance with guidelines.
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Introduction
Chronic heart failure (CHF) affects about 26 million
adults in the world [1], approximately 1–2% of the
population [2], and projections show that its preva-
lence will increase further [3]. In 2012, CHF was the
most prevalent cause of hospitalization among cardio-
vascular disorders in Poland and it was mainly related
to a high number of early readmissions as it con-
cerned up to 60% of CHF patients within 30 days of
discharge [4,5]. Moreover, between 25% and 75% of
these early re-hospitalizations may have been prevent-
able if optimal management and more comprehensive
care for CHF patients had been introduced [4,6,7].
During the last decade, most of the large studies con-
ducted in Poland reported data on CHF management
in hospital settings or cardiology outpatient clinics [8].
Meanwhile, some data indicate that Polish primary
care physicians (family doctors and general internists)
are key persons in taking care of CHF patients, and
each primary care physician treats from 7–36 CHF
patients [7]. These patients are usually older than CHF
patients under the care of cardiologists [9].
Within the National Programme for Prevention of
Cardiovascular Diseases (POLKARD 2005), a series of
nationwide surveys was conducted in randomly
selected primary care settings to assess adherence to
guidelines on CHF management with regard to the
diagnosis and treatment procedures [9–11]. The
changes that have taken place in Poland over the last
decade (see Box 1) have prompted a repetition of the
survey in 2013. The aim of the present study was to
assess the current CHF management in primary care
settings in Poland. The study was designed to answer
the following research questions:
1. Do Polish primary care physicians have access or
perform basic diagnostic procedures for CHF
patient?
2. What are the drugs prescribed to CHF patients by
Polish primary care physicians?
3. What is the rate of referrals to the secondary care
of CHF patients seen by primary care physicians?
4. Have diagnostic and therapeutic procedures for
CHF patients changed since the previous survey
dated in 2005?
METHODS
Study design
The study was a nationwide, retrospective survey per-
formed according to the principles of the previous sur-
vey edition in 2005 [9,11]. A trained nurse contacted
one physician drawn from the list of all doctors pro-
viding medical care at the selected primary care
centre. The selected physician was asked to provide
accurate data on the management of the last five CHF
patients, consulted within the last 365 days before the
survey. Data on patients’ characteristics (sex, age,
NYHA class, and comorbidities), specific for CHF diag-
nostic procedures (echocardiography, NT-proBNP) and
pharmacotherapy (class of drugs) have been collected.
The field studies were carried out from April to
November 2013.
Selection of participating primary care centres
The sampling frame was the Polish nationwide registry
of entities carrying out medical activities available at
https://rpwdl.csioz.gov.pl—in April 2013. Out of all set-
tings providing primary care a proportional stratified
multistage sample of 390 primary care centres was
selected. Random selection was held in each stratum
defined by the province and size of the town in such
a way that the number of primary care centres was
proportional to the fraction of the population that the
stratum constitutes in the general population. In the
selected primary care centre, the physicians were ran-
domly chosen from the list of primary care physicians
employed in the centre.
Box 1. Summary of changes which have been introduced in
Poland during the last decade to improve the quality of
outpatient care addressed to the patients with chronic
heart failure (CHF).
 Implementation of the National Programme of Equalization of
Accessibility for Prevention and Treatment of Cardiovascular
Diseases (POLKARD 2010–2012) funded by the Polish Ministry
of Health thanks to which many outpatient specialist care
units had been equipped with medium and high-class echo-
cardiographic devices.
 Educational projects promoting the guidelines of the
European Society of Cardiology on CHF management at
national and local levels. The projects were addressed both
to primary care physicians as well as cardiologists and intern-
ists and were organized by or in cooperation with experts
from the Polish Society of Cardiology.
 Development of initiatives to improve the cooperation
between cardiologists and family doctors and the information
flow about patients (e.g. joint guidelines of family physicians
and cardiologists on heart failure management, CHF patients’
passport, etc.).
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Inclusion and exclusion criteria
Patients who had ever been diagnosed with CHF
were included in the study. The diagnosis of CHF
had to be available in the patients’ medical records
and the primary care physician had to be convinced
of the presence of CHF (based on medical records at
patients’ discharge from the hospital or a cardiolo-
gist) and treated that patient during the previous
year as a CHF patient. CHF did not have to be the
direct reason for encounter. A currently treated onco-
logic condition was a criterion for exclusion from the
study.
Statistical analysis
Continuous variables were summarized as mean± stan-
dard deviation (SD). Ordinal variables or variables with
skewed distribution were presented as median and
interquartile range (IQR). Data on prevalence were
given as numbers (percentages). The comparative anal-
yses were based on Student’s t-test or the Wilcoxon
test, and the chi-square test. The Cochrane–Armitage
trend test was used to assess age-related changes in
pharmacological therapy of CHF. Two-sided tests were
used and the P-value<0.05 was considered as
significant.
Data were managed and analysed using SAS v. 9.3
(SAS Institute Inc., Cary, NC, USA).
Ethical issues
Data were collected and processed maintaining confi-
dentiality and anonymity of the surveyed patients and
the primary care physicians participating in the study.
The study was approved by the Bioethics Committee
of the Jagiellonian University (approval no. KBET/71/B/
2011)—opinion dated 28 June 2012, and was valid
until 31 December 2013.
Results
The surveyed primary care centres mostly operated
within the structures of private healthcare institutions,
acting as an independent contractor within the public
healthcare system. The participating physicians were
mostly family physicians (63%) and specialists in
internal medicine (38%), 7% were cardiologists and 2%
were geriatricians.
The mean age (± SD) of the 2006 surveyed CHF
patients was 72 years (± 11); 45% were women, 74%
had ischaemic history of CHF. The baseline
characteristics of the patients was summarized and
compared from the study population from 2005 in
Table 1. In comparison to the 2005 study, the sur-
veyed patients were significantly older—the number
of octogenarians increased by 10%. Moreover,
slightly more CHF patients had a history of myocar-
dial infarction, valvular heart disease and atrial fibril-
lation. A higher prevalence of chronic comorbidities
was observed.
Diagnosis of heart failure
The diagnosis of CHF was supported by echocardiog-
raphy in 67% of the patients in primary care settings
surveyed in 2013, although the small changes regard-
ing to the accessibility of the echocardiography in pri-
mary care settings were observed (Table 2). In general,
diagnosis of CHF was based on the presence of CHF
symptoms (93%) and results of ECG (82%) and/or
chest X-ray (76%). Echocardiography was less fre-
quently performed in women than in men (62% versus
71%, P<0.001) and in very old patients (80 years)
than in younger subjects (50% versus 72%, P<0.001).
The data from the last echocardiography of the sur-
veyed CHF patients, available for primary care physi-
cians has shown the median of the left ventricular
ejection fraction (LVEF) equal to 45% (interquartile
range: 35–55%). Of these, 43% have the normal ejec-
tion fraction.
Access to the serum concentration of N-terminal of
the prohormone BNP (NT-proBNP) has improved,
although it was still infrequently used in primary
healthcare and the procedure was made only in a
small group of patients (Table 2).
Other diagnostic procedures and specialist
consultations
During the year preceding the survey 24-h ECG was
performed in 24% patients, spirometry in 17%, an
exercise stress test in 19%, and 4% of the patients had
undergone ergospirometry or the six-minute walk test.
In addition, 77% of the CHF patients were referred to
cardiologists, however with advancing age, the fre-
quency of the referrals steadily decreased—from 92%
in patients below 50 years of age to 70% among
octogenarians, and 60% in 90-year-old patients.
To psychologists, physiotherapists or dieticians were
referred respectively 10%, 8% and 4% of the patients.
During the last visit, primary care physicians recog-
nized functional disability, cognitive decline and
depressive symptoms, in respectively: 31%, 21% and
8% of the patients.
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Table 2. Accessibility of echocardiography and NT-proBNP for the surveyed primary care
centres and presentation of the available results. Data are presented as means ± standard
deviation, median [upper - lower quartile] or number (percentage).
2013 2005 P-value
Number of surveyed primary care centres 390 400
Accessibility of the diagnostic procedures:
Echocardiography, n (%)
<1 month 53 (13.5) 52 (13.0) <0.001
1–3 months 61 (15.6) 90 (22.5)
>3 months 74 (19.1) 55 (13.8)
Not available 176 (45.2) 166 (41.5)
Missing data 26 (6.7) 37 (9.3)
NT-proBNP, n (%)
<1 month 77 (19.7) 14 (3.5) <0.001
1–3 months 25 (6.5) 7 (1.8)
>3 months 8 (2.1) 4 (1.0)
Not available 232 (59.6) 311 (77.7)
Missing data 48 (12.2) 64 (16.0)
Results available to primary care physicians
LVEF, %
Available data, n (%)a 1342 (66.9) 683 (34.2) <0.001
LVEF, mean ± SD 44.8 ± 13.1 45.4 ± 14.1 0.285
Reduced (<40%) 419 (31.2) 222 (32.5) 0.527
Borderline (40–49%) 347 (25.9) 161 (23.6)
Preserved (50%) 576 (42.9) 300 (43.9)
NT-proBNP, pg/ml
Available data, n (%)b 79 (3.9) –
NT-proBNP, median [Q1–Q3] 1492 [850–3128] n.a.
NT-proBNP: N-terminal prohormone brain natriuretic peptide; LVEF: left ventricular ejection fraction; n.a.: not
available.
aThe last available examination.
bMeasured within the last three months before the inclusion in the survey.
Table 1. Clinical characteristics of CHF patients in primary care settings in 2013 in compari-
son to 2005. Data are presented as means ± standard deviation or number (percentage).
2013 2005 P-value
Number of patients’ medical records surveyed 2006 2000
Women, n (%) 861 (44.8) 904 (47.0) 0.381
Age, years 71.9 ± 11.0 68.8 ± 11.8
Age categories, n (%)
<60 years 315 (15.7) 487 (24.3) <0.001
60 69 years 414 (20.6) 433 (21.6)
70 79 years 687 (34.3) 695 (34.8)
80þ years 584 (29.1) 374 (18.8)
Missing data 6 (0.3) 11 (0.5)
NYHA class, n (%)
I 41 (2.0) 79 (4.0) <0.001
II 1117 (55.7) 936 (46.8)
III 763 (38.0) 876 (43.8)
IV 62 (3.1) 98 (4.9)
Missing data 23 (1.2) 11 (0.5)
Cardiovascular comorbidities, n (%)
Hypertension 1646 (82.1) 1678 (83.9) 0.129
Coronary heart disease 1476 (73.6) 1632 (81.6) <0.001
Myocardial infarction 748 (37.3) 682 (34.1) 0.035
Stroke or TIA 337 (16.8) 335 (16.8) 1.000
Dilated cardiomyopathy 312 (15.6) 349 (17.5) 0.106
Other cardiomyopathies 284 (14.2) 313 (15.7) 0.183
Valvular heart disease 583 (29.1) 402 (20.1) <0.001
Atrial fibrillation 1010 (50.3) 768 (38.4) <0.001
Other comorbidities, n (%)
Diabetes 678 (33.8) 617 (30.9) 0.049
Chronic kidney disease 413 (20.6) 188 (9.4) <0.001
Thyroid diseases 345 (17.2) 238 (12.0) <0.001
CHF: chronic heart failure; NYHA: New York Heart Association; TIA: transient ischaemic attack.
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Pharmacotherapy
Usage of the drug classes dedicated to CHF therapy as
well as other cardiovascular medications was summar-
ized in Table 3.
There were no significant differences between
women and men in the use of angiotensin inhibition
therapy and b-blockers (alone or combined with
angiotensin inhibition), as well as in MRAs and digitalis
use. The only difference was in the use of diuretics—
frequently more in women than men (85% versus
77%, respectively, P< 0.001).
A significant increase in the use of b-blockers alone
or with angiotensin inhibitions were observed when
compared to the previous survey from 2005 as well as
the loss of discrepancies in the use of b-blockers in
younger and older patients (Figure S1, available
online). Moreover, the percentages of CHF patients on
digitalis therapy were decreased, whereas with age a
more frequent use of diuretics and less frequent use
of MRAs were observed.
Discussion
Main findings
The study has indicated that in the two-thirds of the
CHF patient’s diagnosis has been confirmed by echo-
cardiography, more often in the younger patients and
men. The use of natriuretic peptides measurements in
diagnostics of CHF was insufficient in everyday med-
ical practice. Most of the CHF patients have received
the drug classes according to the guidelines but there
is still room for improvement. Compared to the previ-
ously study edition, the percentage of CHF patients in
primary care whose diagnosis was supported by echo-
cardiography significantly increased. Regarding the
CHF therapy, a significant increase in the usage of
neurohormonal inhibitors was observed, especially in
the patients over 70 years of age.
Interpretation of the study—the results in relation
to existing literature
Observed in our survey, a better implementation of
echocardiography in primary care in Poland suggests
that CHF diagnostics is more objective and more com-
pliant to the current ESC guidelines. In our study, 67%
of the CHF patients had undergone echocardiography
and these results were available for primary care physi-
cians. Very similar data were obtained in an Italian
study, where 57% of all subjects had a diagnostic
echocardiography record [12]. Moreover, the age-
related inequalities observed in our study were also
visible in the above-mentioned study as well as in
other countries, both in primary care and in long-term
care settings [13,14].
Table 3. Pharmacological management of CHF and concomitant therapy of cardiovascular
diseases in primary care settings – data from 2005 and 2013.
Pharmacotherapy in CHF patientsa 2013 2005 P-value
Available data n 1384 2000
Drugs used in the CHF patients, n (%)
ACEIs or ARBs 1104 (79.8) 1641 (82.1) 0.093
sz-blockers 1213 (87.6) 1362 (68.1) <0.001
ACEIs or ARBs and sz-blockers 982 (71.0) 1138 (56.9) <0.001
Diuretics 1117 (80.7) 1490 (74.5) <0.001
MRAs 577 (41.7) 963 (48.2) <0.001
Digitalis 225 (16.3) 644 (32.2) <0.001
Ivabradine 5 (0.4) n.a.
Other CV drugs, n (%)
Lipid-lowering drugs 949 (68.6) 894 (44.7) <0.001
Anti-arrhythmic drugs 87 (6.3) 107 (5.4) 0.270
Antiplatelet drugs 711 (51.4) 1004 (50.2) 0.492
Oral vitamin K antagonists 500 (36.1) 382 (19.1) <0.001
NOACs 52 (3.8) n.a.
Potassium supplementation 422 (30.5) 505 (25.5) 0.001
Ca-channel blockers, dihydropyridine 345 (24.9) 368 (18.4) <0.001
Ca-channel blockers non-dihydropyridine 14 (1.0)
Alpha-blockers 120 (8.7) 105 (5.3) <0.001
Trimetazidine 94 (6.8) 176 (8.8) 0.035
Nitrates 132 (9.5) 841 (42.1) <0.001
Vasodilators (peripheral)b 132 (3.9) n.a.
CHF: chronic heart failure; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor
blockers; MRAs: mineralocorticoid receptor antagonists; CV: cardiovascular; NOACs: non-vitamin K antagonist
oral anticoagulants.
aData based on the medical records indicating drugs taken by the patients.
bVasodilators (peripheral): nicergoline, pentoxifylline.
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The data on CHF diagnosis as well as the man-
agement obtained from primary care settings are
more difficult to evaluate because of the frequent
problem with validation of CHF diagnosis. Some
studies highlighted the problem of either misdiag-
nosing or failing to recognize CHF as well as over-
diagnosis of CHF in primary care [14–18]. In Poland,
echocardiography is still not a diagnostic procedure
routinely available in primary care settings; therefore,
the effort should be probably provided to more
common use of natriuretic peptides diagnostic tests
[6,7]. Taking into account the recently published
data [16], some indirect evidence for a truly existing
CHF in our patients may be history of cardiologic
consultation—77% of the surveyed patients were
consulted during the last year by the cardiologist. In
addition, the reliability of the CHF diagnosis increase
the ischaemic aetiology of CHF observed in most of
our patients.
The study findings confirm that noticeably more CHF
patients in primary care settings are currently being
treated in line with evidence-based medicine and the
current recommendations [6,7,19]. In Poland, 15 years
ago, ACEIs, b-blockers, diuretics and digitalis were used
by 65%, 34%, 57% and 39% of CHF patients [20].
Comparing our findings to the data from the ESC-
HF registry, originating from a similar period, we found
that the use of b-blockers, diuretics and ACEIs was
similar despite differing settings of care and was 89%,
83% and 67%, respectively [8]. Reduced use of MRAs
in our survey (42% versus 59%) can be explained by
the significantly older CHF population—more than
60% of our patients were 75 years of age and older,
compared to 26% of the patients in the ESC-HF regis-
try [8]. Moreover, approximately 50% of our subjects
had a normal LVEF—this is generally in line with the
data on the prevalence of CHF with preserved LVEF
[7,21]. In light of the existing evidence, the analysis of
guideline adherence for the pharmacotherapy of CHF
in our population should in fact, be limited to using
the neurohormonal blockade as an effective method
in the reduction of all-cause mortality in CHF with pre-
served LVEF [22,23].
As CHF patients in primary care settings are usually
older [9,18] and suffer from multimorbidity [24], for
optimal management, it appears necessary to look at
them through the prism of a comprehensive geriatric
assessment [19]. The published studies confirm that
functional decline, frailty syndrome, depression and
cognitive impairment are independent predictors of
short- and long-term mortality among elderly patients
with CHF [25–27].
The strength and limitations of the study
The strength of the study is the large number of the
surveyed primary care centres and nationwide cover-
age. Our study seems to reflect everyday practices in
the management of CHF patients in primary care
because the data comes from patients who have
already been diagnosed and are currently treated due
to CHF.
One of the main limitations of the present study is
the potential selection bias of the patients reported by
primary care physicians. Despite strong recommenda-
tions for the physicians and detailed information pro-
vided by specially trained nurses that CHF patients
should be recruited as the last five to have recently
visited the office of a given primary care physician, we
cannot rule out the possibility that the selection of
patients was based on the primary care physicians’
preferences.
Due to the retrospective study design, a major limi-
tation of our study seems to be the lack of external
verification of the CHF diagnosis as well other col-
lected data.
These study limitations occurred both in the 2005
and 2013 surveys.
An additional limitation in 2013 was a high percent-
age of missing data in echocardiography results, exter-
nal consultations as well as pharmacotherapy regimen
partly resulting from the gaps in the patients’ files.
Because of the inability to verify the data on pharma-
cotherapy, we decided to exclude such incomplete or
uncertain data from our analysis.
Recommendations for clinical practice and further
research
Keeping in mind that in Poland echocardiography is
a diagnostic procedure, which is not performed dir-
ectly in primary care settings, the results of the study
should open the discussion how to change the situ-
ation and improve the accessibility, both to echocar-
diography and NT-proBNP serum concentration for
the patients of a family physician. Assessment of the
effectiveness of their use in primary care settings
should be the subject of future research. A further
popularization of CHF guidelines is needed to opti-
mize the pharmacotherapy regimen in CHF patients,
both in regard to the use of recommended class of
drugs (e.g. angiotensin inhibition) and probably the
optimal doses of drugs. Given that the CHF popula-
tion is getting older, a further educational effort is
needed to improve the implementation of geriatric
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evaluation basis to the clinical practice of family
physicians.
Conclusion
During the last decade, an improvement in the use of
echocardiography in CHF diagnostics in primary care
has been observed in Poland, although its accessibility
has not improved. A minority of the primary care
centres declared access to NT-proBNP measurement
and only a few percent of the CHF patients had this
diagnostic test performed. There still exists an inequity
in performing echocardiography concerning geriatric
patients and women. Such disparities were not visible in
the first-line CHF treatment drug classes. Most CHF
patients received drug classes in accordance with
guidelines.
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